about
Klotho in cardiovascular disease: Current and future perspectivesNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System BlockadeThe Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent YearsDiabetic kidney disease: from physiology to therapeuticsShould we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.Inflammation in diabetic kidney diseaseBaseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort studyImplications of Klotho in vascular health and disease.Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.Inflammatory cytokines in diabetic nephropathy.Vascular calcification in patients with nondialysis CKD over 3 yearsPathophysiological role and therapeutic implications of inflammation in diabetic nephropathyInfluence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease.The role of inflammatory cytokines in diabetic nephropathy.What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study.Pathogenic perspectives for the role of inflammation in diabetic nephropathy.Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy.Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration.Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.Inflammatory pathways.FGF23/Klotho axis: phosphorus, mineral metabolism and beyond.ENaC modulators and renal disease.Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study.[Fibroblast growth factor 23/Klotho system in the context of cardiovascular damage].Expression of FGF23/KLOTHO system in human vascular tissue.Soluble levels and endogenous vascular gene expression of KLOTHO are related to inflammation in human atherosclerotic disease.Phenotypic Modulation of Cultured Primary Human Aortic Vascular Smooth Muscle Cells by Uremic Serum.Urinary Clara Cell Protein in Kidney Transplant Patients: A Preliminary Study.Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients.Reduced Klotho is associated with the presence and severity of coronary artery disease.Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathyAssociation of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease
P50
Q26775409-141AAF27-D6ED-4AF0-83CE-D291ACA50262Q26777994-4A6FEBA2-BE89-4C9A-A51C-CA2EB07FBF75Q26799443-E9C2294C-7860-4D3C-98B9-A63934A791D5Q26799468-C3C97520-E8BC-47E5-B84F-D0357D58823FQ27021392-465F026B-E411-4B5B-A2A3-FC408C2809E1Q31073395-BC514CC2-D757-4CBE-BDB5-DFB835688A03Q33798334-622F7DDA-AB6B-4A6A-B468-394DD032135FQ34023543-B63474DB-2DF3-4DCD-A1E5-09896D1ABE39Q34039724-26F1DCEC-1D12-4860-A7CC-2E335574CF1DQ34780123-51A7ABA0-A914-49D1-BF7F-B8B8520661C5Q34787799-C8F0FB4F-5D97-467A-A63C-50BB4A0D92B5Q35133177-FBF5EDDE-2FE6-4A68-A8E7-59A753E9DABDQ35278497-7FCD5F04-ED1D-456E-A0B1-6F2280FB293AQ35673446-291C036F-FBD2-4F1A-BAC3-52AA59264C8AQ36476878-D8EAAD89-C3DD-41CF-A81E-919A85017488Q37078749-728FFDFB-EA1C-45EA-9473-787457B1233BQ37231813-A29C1496-9E65-4813-8D0D-5CBDC86E0ED8Q37378445-3D55C0AA-5A29-489B-B4BE-A11FAAD7202FQ37387708-AA9A9344-936A-4E5B-9B55-9FB40AE8EB0AQ37404218-90B6DE15-2F38-4E57-ADFA-07025A026B9FQ37542842-380FB9C1-B24D-42E5-BD3F-2AB5980C7304Q37553481-4F6A746A-5268-47DC-A1F4-D8F4773AC7A3Q37871339-38E7CDD9-3886-4293-B61A-27DB20F1D8BEQ37887387-D5DF150F-C670-4924-997C-E67D92BD0AB8Q37987643-09090A88-1F51-4A8D-B183-01D085749DA4Q38095133-9C6587E8-7F3C-41E4-9ECB-321B6CF5DC61Q38205525-0AB42C6C-5783-4A19-BDF0-5AA357E7D416Q41584685-3BBFBDFE-0978-43B4-BD47-EEA91C084623Q42480950-09E1C3CB-419F-49B3-8CE3-FC734DC8B777Q42688333-3F31EEC7-91C1-4ADF-934B-8EA332AA2C5BQ44503036-10D28490-6AD2-45A3-BBC3-0BED065D6B33Q44839652-0ED84E23-579A-40C3-9481-EE95AA81B66BQ47722984-B339CAC2-E371-442F-B184-1E64D10C87D3Q50300037-A49F5B51-88D5-4693-9DA0-A2F7D856E994Q51278549-757D8915-5892-40E6-8A27-439CD9B53C35Q51610568-7621FD3F-B78E-40B7-87DB-0529DBD50E13Q54237788-E7FE90DE-8B64-4FC1-A2AA-A90CC559E8BEQ57048932-7E955A74-BBD2-439E-A660-E9D33782DEE6Q62933141-4BF9B9F9-64EB-4CF6-8EBE-C70D8FEF7C52Q63258846-66F0FD4A-DBF2-4B77-AE8A-F3C2ED437FC2
P50
description
researcher ORCID ID = 0000-0002-5015-7474
@en
wetenschapper
@nl
name
Juan F Navarro-González
@ast
Juan F Navarro-González
@en
Juan F Navarro-González
@nl
type
label
Juan F Navarro-González
@ast
Juan F Navarro-González
@en
Juan F Navarro-González
@nl
prefLabel
Juan F Navarro-González
@ast
Juan F Navarro-González
@en
Juan F Navarro-González
@nl
P21
P31
P496
0000-0002-5015-7474